Clinical Trial Search

Primary: Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects) — 32.9; 18.9 Percentage of subjects

Primary: Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction — 15.6; 10.0; 82.1; 86.7 Percentage of participants

Primary: Global PCR (Conventional PCR and Real-time Quantitative PCR) Immediately After the End of Treatment. — 16; 20 Participants

Primary: Correlation Between Longitudinal Global Strain and the Percentage of Myocardial Fibrosis on Magnetic Resonance — 16.8 percentage of fibrosis

Primary: PRISM Chagas Specificity — 23; 16223; 3 participants

Primary: ESA Chagas Testing of US Blood Donor Specimens Repeatedly Reactive by ABBOTT PRISM Chagas — 92.06 percent agreement to RIPA

Primary: Percentage of Participants With Late-stage HAT Whose Treatment Outcome Was a Success at Month 18 According to Adapted World Health Organization (WHO) Criteria — 95.2…

Primary: Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From…

Primary: Number of Patients With Adequate Clearance of Parasites and Symptoms — 110 Participants

Primary: Percentage of Participants Whose Treatment Outcome at Month 18 is a Success — 93.1 percentage of participants

Primary: Occurrence of Any TEAEs — 195; 69 Participants

Primary: Percentage of Patients Screened Positive for One of the Disorders — 17.5; 3.1; 1.8; 0.8 percentage of participants

Primary: Percentage of Evaluable Patients With Stage 2 r-HAT Who Died by the End of Hospitalization, Considering Only Deaths Possibly Related to r-HAT or Fexinidazole — 0…

Primary: Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled — 61; 88; 90 participants

Primary: Percent of Participants With Final Clinical Cure — 78.6; 77.8 percent of participants

Primary: Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection at Baseline — 30.7; 30.3; 31.1; 30.5 community

Primary: Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 12 — -2.0; -0.5; -3.1; -1.2 percent of CD8 expressing HLA-DR+/CD38+ — p=0.428

Primary: Number of Patient With Lack of Objective Clinical Improvement — 0 Participants

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of First Vaccination — 0; 1; 1; 0 participants

Primary: Assessment of DENV, ZIKV, CHIKV Seroprevalence Via Screening PRNT50 Titers in Cambodian Adults. — 300 Participants

Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097

Primary: Percentage of Participants With Parasite Clearance at Day 28 — 97.20 percentage of participants

Primary: Feasibility as Measured by the Number of Total Scheduled Intervention Sessions (CHW Counseling Sessions, Doctor's Visits, Phone Calls) Attended — 589 Scheduled sessions

Primary: Cross-reactive Antigenemia — 12 Participants

Primary: Insulin Sensitivity — .56; 0.55; 0.66; 0.70 % suppression inf rate 56 pmol/m2/min

Primary: Frequency of Adverse Events in the CHMI-trans Model — 95; 95; 107; 52 Adverse events

Primary: Number of Patients With Neutrophil Engraftment — 2 participants

Primary: The Primary Safety Endpoint - Frequency of Complications of Therapy — 414 participants

Primary: Primary Survival — 19; 13 participants — p=0.43

Primary: Recurrent Trichiasis in Tetracycline and Azithromycin Groups — 45; 62 Participants — p=.047